Methods
AssigneeGlaxoSmithKline Intellectual Property Development Limited
InventorsAnne Marie Jeanne BOUILLOT, Alexis DENIS, John LIDDLE, Olivier MIRGUET, Ann Louise WALKER
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and/or uses for treating pancreatitis, kidney diseases and other various disorders as described herein, for conditions or disorders mediated by KMO inhibitors, which comprises administering 6-chlorobenzoxazine compounds of Formula (I): or pharmaceutically acceptable salts and/or corresponding pharmaceutical compositions thereof.
Claims22
A method for treating pancreatitis, which comprises administering a compound of Formula (I):
- wherein:
- R1 is heteroaryl optionally substituted by methyl, ethyl, or halo;
- and
- R2 is H, methyl or ethyl;
- or
- a pharmaceutically acceptable salt thereof to a patient in need thereof.
A method for treating pancreatitis, which comprises administering a therapeutically effective amount of a pharmaceutical composition to a patient, wherein the pharmaceutical composition comprises:
- a) a therapeutically effective amount of a compound of Formula (I):
- wherein:
- R1 is heteroaryl optionally substituted by methyl, ethyl, or halo;
- R2 is H, methyl or ethyl;
- or
- a pharmaceutically acceptable salt thereof to a patient in need thereof;
- and
- b) a at least one pharmaceutically acceptable excipient(s).
A method for treating kidney disease, which comprises administering a compound of Formula (I):
- wherein:
- R1 is heteroaryl optionally substituted by methyl, ethyl, or halo;
- and
- R2 is H, methyl or ethyl;
- or
- a pharmaceutically acceptable salt thereof to a patient in need thereof.
A method for treating kidney disease, which comprises administering a therapeutically effective amount of a pharmaceutical composition to a patient, wherein the pharmaceutical composition comprises:
- a) a therapeutically effective amount of a compound of Formula (I):
- wherein:
- R1 is heteroaryl optionally substituted by methyl, ethyl, or halo;
- R2 is H, methyl or ethyl;
- or
- a pharmaceutically acceptable salt thereof to a patient in need thereof;
- and
- b) a at least one pharmaceutically acceptable excipient(s).
A method for treating acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel disease, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure, which comprises administering a therapeutically effective amount of a compound of Formula (I):
- wherein:
- R1 is heteroaryl optionally substituted by methyl, ethyl, or halo;
- and
- R2 is H, methyl or ethyl;
- or
- a pharmaceutically acceptable salt thereof to a patient in need thereof.
Dependencies are inferred from the claim text.